Porcine vaccines are used clinically to ameliorate swine condition by guarding them against viruses, bacteria, and other pathogens. The porcine vaccine market is mainly driven by the demand for gelatin and pork meat, and a rise in the prevalence of swine diseases. Increasing R&D investments by vaccine manufacturing companies, government initiatives, and demand for porcine meat are some of the major factors propelling market growth. For instance, the International Livestock Research Institute (ILRI) started initiatives carry out pig farming more efficiently in 2014.

In May 2019, Hipra launched two new swine vaccines in the South Korean market for regional expansion. Moreover, the rising demand for meat, milk and animal proteins and growing concern over the prevalence of zoonotic diseases are factors driving the market. Vietnam is the third largest pig meat eating country in the world, where an average of 29.14 kg of pig meat was consumed in 2015

The ongoing research regarding medical advancements in animal vaccines is expected to fuel market growth in the coming years. For instance, in 2017, researchers from the US and Australia uncovered genetic data that may help in developing a vaccine for American swine fever. The high disease prevalence with regards to swine health is seen in some countries such as Africa, Sardinia, The Russian Federation, and a few Eastern European countries.

Based on technology, the global porcine vaccine market has been segmented into the live attenuated virus, inactivated vaccines, recombinant vaccines, toxoid vaccines, conjugate vaccines, and DNA vaccines. The inactivated vaccine is expected to witness lucrative growth during the forecast period. This growth can be attributed to low cost, technological advancements, easy availability, and low risk of revert action. 

Based on disease type, the market can be segmented into diarrhea, arthritis, swine influenza, pneumonia, Porcine Reproductive and Respiratory Syndrome (PRRS), Porcine Circovirus Associated Disease (PCVAD), and others (leptospirosis, CHRS). The swine influenza segment is expected to witness growth, owing to climate change due to global warming, overfeeding of protein diet, and increasing occurrence of genetically modified influenza strains. Diarrhea and PCVAD segments are also expected to witness significant growth due to ongoing research on the development of recombinant vaccines.

Based on end-use industry, the market has been segmented into veterinary hospitals and hog production firms. The growth of the hog production firms segment can be attributed to the increased breeding of pigs for meat and other products. The market has been studied for North America, Eastern Europe, Western Europe, Asia Pacific, Middle East, and Rest of the World.

The market is highly competitive in nature. Key market players includeCeva Santé Animale, Boehringer Ingelheim GmbH, Merck & Co., Inc., Elanco, and Zoetis.Companies are engaging in different strategies such as mergers&acquisitions, regional expansions, new product launches, and collaborations to increase their market share.

Key Factors Impacting Market Growth:

  • Increasing market demand for porcine vaccines
  • High demand from the healthcare sector
  • Increasing meat and animal protein consumption worldwide
  • Rising demand for recombinant vaccine technology 

Market Segmentation:

By Technology Type:

  • Live Attenuated Vaccines
  • Inactivated Vaccines
  • Recombinant Vaccines
  • Toxoid Vaccines
  • Conjugate Vaccines
  • DNA Vaccines 

By Disease Type:

  • Diarrhea
  • Arthritis
  • Influenza
  • Pneumonia
  • Porcine Reproductive and Respiratory Syndrome (PRRS)
  • Porcine Circovirus Associated Disease (PCVAD)
  • Others

By End User

  • Veterinary Hospitals
  • Hog Producing Firms 

By Region:

  • North America
    • By Country (US, Canada, Mexico)
    • By Technology
    • By Disease Type
    • By End User
  • Western Europe
    • By Country (Germany, UK, France, Italy, Spain, Rest of Western Europe)
    • By Technology
    • By Disease Type
    • By End User
  • Eastern Europe
    • By Country (Russia, Turkey, Rest of Eastern Europe)
    • By Technology
    • By Disease Type
    • By End User
  • Asia Pacific
    • By Country (China, Japan, India, South Korea, Australia, Rest of Asia Pacific)
    • By Technology
    • By Disease Type
    • By End User
  • Middle East
    • By Country (UAE, Saudi Arabia, Qatar, Iran, Rest of Middle East)
    • By Technology
    • By Disease Type
    • By End User
  • Rest of the World
    • By Region (South America, Africa)
    • By Technology
    • By Disease Type
    • By End User 

Companies Covered: Ceva Santé Animale, Boehringer Ingelheim GmbH, Merck & Co., Inc., Elanco and Zoetis… 

Reasons To Buy This Report:

  • Market size estimation of the porcine vaccines market on a regional and global basis
  • The unique research design for market size estimation and forecast
  • Profiling of major companies operating in the market with key developments
  • Broad scope to cover all the possible segments helping every stakeholder in the market


We provide customization of the study to meet specific requirements:

  • By Segment
  • By Sub-segment
  • By Region/Country

For more information, contact:sales@quincemarketinsights.com


License Offerings

Single User License - USD 3999

Multi User License - USD 5499

Corporate License - USD 6999

Why QMI?

Detailed Coverage

Detailed scope covering all the major segments in the market

Meticulous Data Validations

In line data validations to ensure data precision


Market recommendations supporting decision making processes

Analyst Support

Round the clock analyst support to resolve your queries

Free Customization

Up to 15% additional free customization to meet your specific requirements

Related Insights:
Close Menu